Belgium commits to autumn relaunch of national biopharma R&D platform

Belgium's Prime Minister has committed to relaunching a national biopharma research and development platform this autumn. This initiative signals a strategic national focus on supporting deeptech research and pharmaceutical innovation within the life sciences sector, aiming to foster public-private partnerships.

The relaunch builds on existing efforts to strengthen health research and innovation. Europe faces numerous health challenges that require robust R&I efforts, with strategies needing harmonisation across different levels and geographical boundaries. The need for cross-border alignment in R&I became particularly evident during the COVID pandemic, as highlighted by the PRIOHealth project, which focuses on R&I policies for better health, wellbeing, and prosperity, and European partnerships for health.

Innovation in biopharmaceuticals is crucial for addressing new therapeutic areas. Projects like BIOPURE demonstrate advancements in biopharmaceuticals purification, focusing on continuous membrane-assisted crystallisation to recover monoclonal antibodies. This project aims to lower manufacturing costs, reduce environmental impact by avoiding extensive chemical use, and simplify logistic chains, representing a significant step in process innovation within industrial biotechnology.

Further illustrating the scope of deeptech in the sector, the GATBIO NEXT project is dedicated to advancing complex biologic drugs. This project targets the development and production of next-generation accessible and non-invasive biologic drugs, showcasing ongoing efforts to bring novel solutions to biopharma markets. Such initiatives align with Belgium's platform goals to push the boundaries of pharmaceutical development.

The forthcoming platform is expected to create a more integrated ecosystem, encouraging collaboration between academic institutions, industry players, and government bodies. This collaborative approach is vital for translating cutting-edge research into tangible health solutions and maintaining Europe's potential as a global hub for clinical studies and trials.

What this means: Belgium's commitment to relaunching this national platform indicates a concerted effort to enhance its competitive edge in the global biopharma landscape. It underscores a strategic investment in deeptech R&D, positioning the country to drive future pharmaceutical breakthroughs and strengthen its life sciences economy.